Bristol-Myers Squibb Company ((BMY)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Study Overview: Bristol-Myers Squibb is conducting an observational study titled Observational, Multicenter Study to Describe the Persistence in Relapsing Remitting Multiple Sclerosis Naive Patients With Low-moderate Activity Treated With Ozanimod (Zeposia®) in Clinical Practice in Spain. The study aims to gather data on the persistence of ozanimod treatment and its effects on outcomes for treatment-naïve participants with relapsing-remitting multiple sclerosis (RRMS), highlighting its significance in real-world clinical settings.
Intervention/Treatment: The study focuses on ozanimod, marketed as Zeposia®, which is a treatment for RRMS. The purpose of this intervention is to assess its persistence and impact on patient outcomes in a clinical practice setting.
Study Design: This is an observational cohort study with a retrospective time perspective. The study does not involve any allocation or masking, as it aims to observe the natural persistence of treatment in patients.
Study Timeline: The study began on June 14, 2023, with its primary completion and estimated overall completion set for June 27, 2025. These dates are crucial for tracking the study’s progress and the availability of results.
Market Implications: The study’s findings could influence Bristol-Myers Squibb’s stock performance by providing insights into the real-world effectiveness of ozanimod, potentially boosting investor confidence. As the pharmaceutical industry is highly competitive, positive results may also impact the market dynamics concerning RRMS treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.